New Delhi, January 27 : Faridabad-based Translational Health Science and Technology Institute is all set to hold the third edition of its basic course in Immunology from March 16 to 18.
Immunological research is critical to treat significant health problems and possesses tremendous potential while developing treatment for emerging diseases that cause significant health burden. Understanding of the immunological mechanisms helps to extend the horizon of knowledge, among other things, for deciphering pathways underlying cancer, autoimmune diseases, and for developing vaccines for emerging pathogens.
“Advancing our understanding of basic, translational and clinical immunology is essential for commercial applications including new diagnostics and treatments to manage a wide range of diseases.
The course possesses tremendous potential in training the next generation of scientists and researchers in immunology” said Dr. Amit Awasthi, Associate Professor, coordinating faculty of the course and also one of its teachers.
Most of the areas in the course will be covered by Dr. Shiv Pillai, Professor, Harvard Medical School, Boston. Joining them this year will be Dr. Dipankar Nandi from the Department of Biochemistry, Indian Institute of Science. The target audience for course are Masters and PhD students, research associates and post-doctoral fellows, early career investigators. However, the course is open to other investigators also who would like to update on the knowledge of Immunology.
The last year’s course was attended by more than 250 participants comprising faculty members, research fellows and PhD students from institutes across the country. Researchers at Banaras Hindu University, AIIMS Delhi, PGIMER Chandigarh, SRM Sonipat, Tezpur University and others could attend by joining a live streaming session.
By Sunderarajan Padmanabhan
(India Science Wire)